Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Regulation of heart rate and the pacemaker current by phosphoinositide 3-kinase signaling.

Lin RZ, Lu Z, Anyukhovsky EP, Jiang YP, Wang HZ, Gao J, Rosen MR, Ballou LM, Cohen IS.

J Gen Physiol. 2019 Jun 19. pii: jgp.201812293. doi: 10.1085/jgp.201812293. [Epub ahead of print]

PMID:
31217223
2.

Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer.

Sivaram N, McLaughlin PA, Han HV, Petrenko O, Jiang YP, Ballou LM, Pham K, Liu C, van der Velden AW, Lin RZ.

J Clin Invest. 2019 May 21;130. pii: 123540. doi: 10.1172/JCI123540.

3.

Acquired long QT syndrome and phosphoinositide 3-kinase.

Cohen IS, Lin RZ, Ballou LM.

Trends Cardiovasc Med. 2017 Oct;27(7):451-459. doi: 10.1016/j.tcm.2017.05.005. Epub 2017 May 17. Review.

4.

Activation of Gαq in Cardiomyocytes Increases Vps34 Activity and Stimulates Autophagy.

Liu S, Jiang YP, Ballou LM, Zong WX, Lin RZ.

J Cardiovasc Pharmacol. 2017 Apr;69(4):198-211. doi: 10.1097/FJC.0000000000000461.

5.

Energy balancing by fat Pik3ca.

Nelson VL, Ballou LM, Lin RZ.

Adipocyte. 2014 Nov 14;4(1):70-4. doi: 10.4161/21623945.2014.955397. eCollection 2015 Jan-Mar.

6.

Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels.

Ballou LM, Lin RZ, Cohen IS.

Circ Res. 2015 Jan 2;116(1):127-37. doi: 10.1161/CIRCRESAHA.116.303975. Review.

7.

Adipose tissue insulin resistance due to loss of PI3K p110α leads to decreased energy expenditure and obesity.

Nelson VL, Jiang YP, Dickman KG, Ballou LM, Lin RZ.

Am J Physiol Endocrinol Metab. 2014 May 15;306(10):E1205-16. doi: 10.1152/ajpendo.00625.2013. Epub 2014 Apr 1.

8.

Increased persistent sodium current due to decreased PI3K signaling contributes to QT prolongation in the diabetic heart.

Lu Z, Jiang YP, Wu CY, Ballou LM, Liu S, Carpenter ES, Rosen MR, Cohen IS, Lin RZ.

Diabetes. 2013 Dec;62(12):4257-65. doi: 10.2337/db13-0420. Epub 2013 Aug 23.

9.

Class IA PI3K p110β subunit promotes autophagy through Rab5 small GTPase in response to growth factor limitation.

Dou Z, Pan JA, Dbouk HA, Ballou LM, DeLeon JL, Fan Y, Chen JS, Liang Z, Li G, Backer JM, Lin RZ, Zong WX.

Mol Cell. 2013 Apr 11;50(1):29-42. doi: 10.1016/j.molcel.2013.01.022. Epub 2013 Feb 21.

10.

Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome.

Lu Z, Wu CY, Jiang YP, Ballou LM, Clausen C, Cohen IS, Lin RZ.

Sci Transl Med. 2012 Apr 25;4(131):131ra50. doi: 10.1126/scitranslmed.3003623.

11.

Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function.

Jaber N, Dou Z, Chen JS, Catanzaro J, Jiang YP, Ballou LM, Selinger E, Ouyang X, Lin RZ, Zhang J, Zong WX.

Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2003-8. doi: 10.1073/pnas.1112848109. Epub 2012 Jan 23.

12.

PI3Ks maintain the structural integrity of T-tubules in cardiac myocytes.

Wu CY, Jia Z, Wang W, Ballou LM, Jiang YP, Chen B, Mathias RT, Cohen IS, Song LS, Entcheva E, Lin RZ.

PLoS One. 2011;6(9):e24404. doi: 10.1371/journal.pone.0024404. Epub 2011 Sep 2.

13.

Restoration of defective L-type Ca2+ current in cardiac myocytes of type 2 diabetic db/db mice by Akt and PKC-ι.

Lu Z, Ballou LM, Jiang YP, Cohen IS, Lin RZ.

J Cardiovasc Pharmacol. 2011 Oct;58(4):439-45. doi: 10.1097/FJC.0b013e318228e68c.

14.

Ablation of PI3K p110-α prevents high-fat diet-induced liver steatosis.

Chattopadhyay M, Selinger ES, Ballou LM, Lin RZ.

Diabetes. 2011 May;60(5):1483-92. doi: 10.2337/db10-0869. Epub 2011 Apr 4.

15.

The class IA phosphatidylinositol 3-kinase p110-beta subunit is a positive regulator of autophagy.

Dou Z, Chattopadhyay M, Pan JA, Guerriero JL, Jiang YP, Ballou LM, Yue Z, Lin RZ, Zong WX.

J Cell Biol. 2010 Nov 15;191(4):827-43. doi: 10.1083/jcb.201006056. Epub 2010 Nov 8.

16.

Loss of cardiac phosphoinositide 3-kinase p110 alpha results in contractile dysfunction.

Lu Z, Jiang YP, Wang W, Xu XH, Mathias RT, Entcheva E, Ballou LM, Cohen IS, Lin RZ.

Circulation. 2009 Jul 28;120(4):318-25. doi: 10.1161/CIRCULATIONAHA.109.873380. Epub 2009 Jul 13.

17.

Rapamycin and mTOR kinase inhibitors.

Ballou LM, Lin RZ.

J Chem Biol. 2008 Nov;1(1-4):27-36. doi: 10.1007/s12154-008-0003-5. Epub 2008 May 15.

18.

Decreased L-type Ca2+ current in cardiac myocytes of type 1 diabetic Akita mice due to reduced phosphatidylinositol 3-kinase signaling.

Lu Z, Jiang YP, Xu XH, Ballou LM, Cohen IS, Lin RZ.

Diabetes. 2007 Nov;56(11):2780-9. Epub 2007 Jul 31.

19.

Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one.

Ballou LM, Selinger ES, Choi JY, Drueckhammer DG, Lin RZ.

J Biol Chem. 2007 Aug 17;282(33):24463-70. Epub 2007 Jun 11.

20.

Reversible heart failure in G alpha(q) transgenic mice.

Jiang YP, Ballou LM, Lu Z, Li Wan, Kelly DJ, Cohen IS, Lin RZ.

J Biol Chem. 2006 Oct 6;281(40):29988-92. Epub 2006 Aug 7.

21.

The increase in human muscle protein synthesis induced by food intake is similar when assessed with the constant infusion and flooding techniques.

Caso G, Garlick PJ, Ballou LM, Vosswinkel JA, Gelato MC, McNurlan MA.

J Nutr. 2006 Jun;136(6):1504-10.

PMID:
16702312
22.

Galphaq binds to p110alpha/p85alpha phosphoinositide 3-kinase and displaces Ras.

Ballou LM, Chattopadhyay M, Li Y, Scarlata S, Lin RZ.

Biochem J. 2006 Mar 15;394(Pt 3):557-62.

23.

A transgenic mouse model of heart failure using inducible Galpha q.

Fan G, Jiang YP, Lu Z, Martin DW, Kelly DJ, Zuckerman JM, Ballou LM, Cohen IS, Lin RZ.

J Biol Chem. 2005 Dec 2;280(48):40337-46. Epub 2005 Oct 6.

24.

Galpha q inhibits cardiac L-type Ca2+ channels through phosphatidylinositol 3-kinase.

Lu Z, Jiang YP, Ballou LM, Cohen IS, Lin RZ.

J Biol Chem. 2005 Dec 2;280(48):40347-54. Epub 2005 Sep 26.

25.

Phospholipase C-independent activation of glycogen synthase kinase-3beta and C-terminal Src kinase by Galphaq.

Fan G, Ballou LM, Lin RZ.

J Biol Chem. 2003 Dec 26;278(52):52432-6. Epub 2003 Oct 15.

26.

Ca(2+)- and phospholipase D-dependent and -independent pathways activate mTOR signaling.

Ballou LM, Jiang YP, Du G, Frohman MA, Lin RZ.

FEBS Lett. 2003 Aug 28;550(1-3):51-6.

27.

Activated G alpha q inhibits p110 alpha phosphatidylinositol 3-kinase and Akt.

Ballou LM, Lin HY, Fan G, Jiang YP, Lin RZ.

J Biol Chem. 2003 Jun 27;278(26):23472-9. Epub 2003 Apr 18.

29.

PI 3-kinase regulation of dopamine uptake.

Carvelli L, Morón JA, Kahlig KM, Ferrer JV, Sen N, Lechleiter JD, Leeb-Lundberg LM, Merrill G, Lafer EM, Ballou LM, Shippenberg TS, Javitch JA, Lin RZ, Galli A.

J Neurochem. 2002 May;81(4):859-69.

30.

Dual regulation of glycogen synthase kinase-3beta by the alpha1A-adrenergic receptor.

Ballou LM, Tian PY, Lin HY, Jiang YP, Lin RZ.

J Biol Chem. 2001 Nov 2;276(44):40910-6. Epub 2001 Aug 31.

31.

Rapamycin-insensitive regulation of 4e-BP1 in regenerating rat liver.

Jiang YP, Ballou LM, Lin RZ.

J Biol Chem. 2001 Apr 6;276(14):10943-51. Epub 2001 Jan 25.

33.
34.

Cell cycle regulation of p70 S6 kinase and p42/p44 mitogen-activated protein kinases in Swiss mouse 3T3 fibroblasts.

Edelmann HM, Kühne C, Petritsch C, Ballou LM.

J Biol Chem. 1996 Jan 12;271(2):963-71.

35.
36.

Positive regulation of the nuclear activator CREM by the mitogen-induced p70 S6 kinase.

de Groot RP, Ballou LM, Sassone-Corsi P.

Immunobiology. 1995 Jul;193(2-4):155-60. Review. No abstract available.

PMID:
8530139
37.

Selective inhibition of p70 S6 kinase activation by phosphatidylinositol 3-kinase inhibitors.

Petritsch C, Woscholski R, Edelmann HM, Parker PJ, Ballou LM.

Eur J Biochem. 1995 Jun 1;230(2):431-8.

38.

Induction of the mitogen-activated p70 S6 kinase by adenovirus E1A.

de Groot RP, Schouten GJ, de Wit L, Ballou LM, van der Eb AJ, Zantema A.

Oncogene. 1995 Feb 2;10(3):543-8.

PMID:
7845679
39.
40.

MAP2 kinase and 70K S6 kinase lie on distinct signalling pathways.

Ballou LM, Luther H, Thomas G.

Nature. 1991 Jan 24;349(6307):348-50.

PMID:
1702881
41.

S6 kinase in quiescent Swiss mouse 3T3 cells is activated by phosphorylation in response to serum treatment.

Ballou LM, Siegmann M, Thomas G.

Proc Natl Acad Sci U S A. 1988 Oct;85(19):7154-8.

43.

Protein phosphatase 2A inactivates the mitogen-stimulated S6 kinase from Swiss mouse 3T3 cells.

Ballou LM, Jenö P, Thomas G.

J Biol Chem. 1988 Jan 25;263(3):1188-94.

44.

Control of S6 phosphorylation during the mitogenic response.

Ballou LM, Jenö P, Thomas G.

Adv Exp Med Biol. 1988;231:445-52. No abstract available.

PMID:
3414443
45.

Identification and characterization of a mitogen-activated S6 kinase.

Jenö P, Ballou LM, Novak-Hofer I, Thomas G.

Proc Natl Acad Sci U S A. 1988 Jan;85(2):406-10.

46.

Purification and characterization of phosphorylase phosphatase from rabbit skeletal muscle.

McNall SJ, Ballou LM, Villa-Moruzzi E, Fischer EH.

Methods Enzymol. 1988;159:377-90. No abstract available.

PMID:
2842603
47.

Subunit structure and regulation of phosphorylase phosphatase.

Ballou LM, Villa-Moruzzi E, Fischer EH.

Curr Top Cell Regul. 1985;27:183-92. No abstract available.

PMID:
3004819
48.

Phosphorylase phosphatase. Interconversion of active and inactive forms.

Villa-Moruzzi E, Ballou LM, Fischer EH.

J Biol Chem. 1984 May 10;259(9):5857-63.

49.

Subunit structure and activation of inactive phosphorylase phosphatase.

Ballou LM, Brautigan DL, Fischer EH.

Biochemistry. 1983 Jul 5;22(14):3393-9. No abstract available.

PMID:
6311247
50.

Activation of skeletal muscle phosphorylase phosphatase. Effects of proteolysis and divalent cations.

Brautigan DL, Ballou LM, Fischer EH.

Biochemistry. 1982 Apr 27;21(9):1977-82. No abstract available.

PMID:
6284210

Supplemental Content

Loading ...
Support Center